Newsletter Tool

Today’s Big News

Jun 7, 2024

Diabetes biotech stock tanks as FDA imposes full clinical hold

Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers

Third Rock’s Rapport reveals upsized $154M IPO

Chutes & Ladders—Sanofi research head Frank Nestle says au revoir

Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs

Last day to nominate a biotech for Fierce Biotech's 2024 Fierce 15!

Featured

Diabetes biotech stock tanks as FDA imposes full clinical hold

By Nick Paul Taylor

Biomea Fusion has suffered another dramatic stock drop, with investors sending the share price down 60% after the FDA imposed a full clinical hold on its diabetes program over liver toxicity concerns.

Ipsen gets hot on cold tumors, inking $1.2B biobucks deal for Marengo's T-cell engagers

By Nick Paul Taylor

Ipsen is hot on Marengo Therapeutics’ ability to treat “cold” tumors. The French drugmaker has agreed to pay Marengo up to $1.2 billion to access a T-cell engager platform for targeting immunologically cold tumors that are typically resistant to immunotherapies.

Third Rock’s Rapport reveals upsized $154M IPO

By Gabrielle Masson

Just a few days after Rapport Therapeutics revealed plans for a $122 million IPO, the epilepsy biotech has unveiled an upsized $154 million offering.

MINIATURE SWINE: Changing the Bias for Nonclinical Studies on Small Molecules and Biologics

Chutes & Ladders—Sanofi research head Frank Nestle says au revoir

By Gabrielle Masson,Andrea Park

Several Sanofi leaders are scattering, including Frank Nestle, M.D., the French pharma’s global head of research and chief scientific officer.

Moderna's MMA candidate nabs spot in FDA pilot for rare disease drugs

By Helen Floersh

Moderna’s methylmalonic acidemia candidate, mRNA-3705, will be developed under the FDA’s milestone-driven START pilot program for rare disease.

Last day to nominate a biotech for Fierce Biotech's 2024 Fierce 15!

By Annalee Armstrong

Fierce 15 is here! Nominations are open now in search of the best and brightest in biotech.

Eli Lilly tipped to leapfrog Eisai, Biogen and take control of $13B Alzheimer's market

By Nick Paul Taylor

Eisai and Biogen’s reign at the top of the Alzheimer’s disease market may be short-lived. While Leqembi is the only game in town today, Bloomberg Intelligence analysts expect Eli Lilly to come from behind and capture half of a $13 billion market by 2030.

A look at the top 10 pharma drug ad spenders

By Ayla Ellison,Ben Adams,Andrea Park

In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report.

Fierce Pharma Asia—Enhertu's encore; Akeso's showstopper; GenScript and Legend's US scrutiny

By Eric Sagonowsky

AstraZeneca and Daiichi Sankyo are looking at moving their antibody-drug conjugate Enhertu into another new breast cancer patient class. Ahead of the American Society of Clinical Oncology annual meeting, a cancer antibody from Akeso and Summit Therapeutics stole the show. More Chinese biopharma players are coming under scrutiny from U.S. lawmakers. Plus more.

Fierce podcasts

Don’t miss an episode

A look at the top 10 pharma drug ad spenders

In this week’s episode of “The Top Line,” the Fierce Pharma Marketing team discusses the annual top pharma drug ad spenders special report.

Coverage pathways for psychedelic therapies

A cell therapy reckoning

Resources

Webinar

Enhance your long-term cell & gene therapy success with pDNA manufacturing solutions

Watch our on-demand webinar video to learn more about the challenges in pDNA manufacturing for gene and cell therapy and how to resolve many of these barriers by partnering with our experts through the adoption of vital manufacturing technologies and strategies.

A Comprehensive and Flexible Approach to CMC for Fab and Fc-Fusion Development Programs

New molecular formats are gaining momentum in today’s market. Characterizing these products and developing robust manufacturing processes can help to usher them to market and provide new treatment options for diseases which are currently challenging to treat. Read this white paper to learn more.

Presented by: Lonza

Whitepaper

Fresenius Medical Care gets 25x faster kidney disease insights

This detailed case study shows how Fresenius Medical Care achieved 25 times faster insights to help kidney disease patients, launching the world’s largest global database of dialysis care with fully anonymized patient data.

Sponsored by: Privacy Analytics, an IQVIA company

eBook

Designing Patient-Centered Endpoint in Rare Disease Trials

To make every rare disease trial count, we design patient-centric, relevant strategies for sponsors and caregivers to produce impactful results every time.